ANALYST-UPGRADE filed
CME Group Inc. (CME) receives a double upgrade from Keefe, Bruyette & Woods (KBW) to Outperform from Market Perform, with a $305 price target (unchanged from prior). Current price is $252.54, implying 20.8% upside to the target. The upgrade is a contrarian call: KBW's 75% accuracy (6 of 8 calls) and 7.6% average return rank it above the median among 12 firms covering CME. Consensus is split: 10 Buy (including 2 Strong Buy), 8 Hold, 3 Sell, mean target $305.93, median $310, high $353, low $230. KBW's $305 target sits at the 40th percentile of the range, below the median. Momentum is positive: 2 upgrades (including Rothschild & Co to Buy on June 11) vs 0 downgrades in the past 30 days. EPS estimates are being revised higher: 30-day revisions up 3 vs 0 down for 0y and +1y periods. Insider selling is notable: CEO Terrence A. Duffy sold $7.75M on May 15, and director Hilda Piell sold $1.75M on May 18, these sales align with the bearish consensus but are partially offset by a $418K insider buy on March 26. Short interest is 55.3% of float, elevated. Bottom line: KBW's upgrade is a high-accuracy, contrarian call that adds bullish conviction, but the $305 target is below the median, suggesting limited near-term upside. Traders should watch for earnings on July 21 for catalyst.